Closing the Cancer Treatment and Cost Gap Behind Bangladesh's ~150K New Cases a Year

Diagnosis

Cancer is now a structural, tier-one burden on Bangladesh's health system, not an episodic shock. The curated problem characterization is blunt: roughly 150 thousand new cases per year, set against a treatment-capacity and cost gap. Those two words, capacity and cost, define the policy failure. The country is generating new patients faster than it can diagnose, treat, and pay for them.

The capacity side is a supply problem. When radiotherapy machines, oncology beds, trained specialists, and chemotherapy supply are concentrated in a handful of facilities, most of the ~150K new patients each year either travel long distances, queue past the point where treatment is still curative, or never present at all. The cost side is a household-finance problem. Cancer care is expensive and prolonged, so without a financing mechanism the bill falls directly on families, pushing treatment out of reach and turning a survivable diagnosis into a fatal one.

Why now: this is flagged as a structural problem on a long horizon, which means the gap compounds. Each year of inaction adds another cohort of roughly 150 thousand patients to a system that is already short on capacity. The lead responsible body in the government registry is the Directorate General of Health Services (DGHS), with the Department of Public Health Engineering as a supporting body. The current_state indicator is not populated, which is itself a finding: DGHS cannot manage a gap it does not yet measure.

Recommended actions

1. Stand up a national cancer treatment-capacity and patient registry. Owner: DGHS. Mechanism: a DGHS circular mandating that every public and private oncology facility report installed treatment capacity (radiotherapy units, oncology beds, specialist headcount) and new-case load into a single registry, replacing the null current_state with a live, published figure. Observable signal: a quarterly DGHS capacity-and-caseload dashboard that converts the ~150K annual case estimate into facility-level demand-versus-capacity numbers.
2. Decentralize treatment capacity into regional cancer centers. Owner: DGHS, with the Department of Public Health Engineering as the supporting body for siting, construction, and safe installation of radiotherapy and oncology infrastructure. Mechanism: a phased capital programme that places functioning oncology units outside the existing concentration points, prioritized by the registry's demand-versus-capacity map. Observable signal: a falling average distance from patient to nearest functioning treatment center, and a rising share of the ~150K annual cases treated outside the legacy hub facilities.
3. Create a cancer financial-protection scheme to close the cost gap. Owner: DGHS, as the policy lead within the public health system. Mechanism: a dedicated budget line and benefits package covering diagnosis and core treatment for cancer patients, so that the cost barrier identified in the problem note no longer determines who gets treated. Observable signal: a rising share of registered patients completing a full treatment course, and a falling rate of treatment abandonment after diagnosis.
4. Secure the chemotherapy and treatment-supply chain. Owner: DGHS. Mechanism: a procurement and stock-monitoring protocol tied to the registry so that every regional center has assured supply before it opens. Observable signal: near-zero stockout days reported across the regional centers in the DGHS dashboard.

Sequencing (first 12 months)

Start with action 1, the registry and capacity circular, because it unlocks everything else. Without it, the current_state stays null and the capacity build (action 2) and financing scheme (action 3) would be sized by guesswork. In the first months, DGHS issues the reporting circular and publishes the first national capacity-and-caseload baseline. That baseline becomes the siting map for the regional centers and the actuarial basis for the financial-protection package. Action 4, supply-chain assurance, is designed in parallel so that newly sited centers (action 2) open with assured chemotherapy stock rather than empty pharmacies.

Risks and constraints

The binding constraint is fiscal. Both the regional-center build (action 2) and the financial-protection scheme (action 3) are recurring-cost commitments, and a dedicated budget line must survive annual budget pressure to be credible. The second constraint is institutional capacity: DGHS leads, but the Department of Public Health Engineering must deliver safe siting and installation on the same timeline, and trained oncology specialists cannot be created by circular alone. The third is data discipline. The registry only works if private facilities comply with the reporting circular; weak enforcement leaves the current_state partially blind and mis-sizes every downstream decision.

Bottom line

Bangladesh adds roughly 150 thousand new cancer patients every year into a system short on both treatment capacity and the financing to pay for it, and the missing current_state figure shows DGHS is not yet measuring the gap it must close. The decisive first move is a DGHS-mandated capacity-and-patient registry, which converts a vague burden into a managed one and sizes the regional centers and financial-protection scheme that follow.